Humanwell Healthcare Group's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, will conduct clinical trials on esketamine hydrochloride injection after receiving the National Medical Products Administration's approval, according to a Shanghai Stock Exchange filing on Thursday.
The antidepressant will be tested as a treatment for depressed patients with acute suicidal ideation or behavior.
The pharmaceutical company invested around 3 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.